** Shares of drug developer Vera Therapeutics VERA.O fall 33.1% to $20.50 premarket
** Rival Otsuka's 4578.T experimental drug for a type of kidney disease showed over 50% reduction in protein in patient's urine in a late-stage trial, co says
** VERA's shares surged 60% on Monday after its experimental kidney disease drug, atacicept, helped significantly reduce harmful levels of proteins in the urine in a late-stage study
** Both companies are developing drugs to treat IgA nephropathy, which causes abnormal protein buildup in the kidneys and could eventually lead to the organ's failure
** Vera's drug atacicept reduced protein levels in patients' urine by 46%, compared with a 7% reduction with a placebo
** Up to last close, VERA down 27.6% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。